rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/410-1893-2023-10-3-6KANTCUrpmj-901Research ArticleОбзорReviewВозможности радиогеномики в оценке ответа и долговременной выживаемости при неоадъювантном лечении рака молочной железыRadiomics of magnetic resonance imaging for assessment of pathological complete response to neoadjuvant therapy and long-term survival in breast cancerhttps://orcid.org/0009-0004-7809-4366ПетроваН. В.PetrovaN. V.

 

Петрова Наталья Витальевна – врач-ординатор отделения лучевых методов диагностики ФГБУ «Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского», г. Москва, Российская Федерация

ORCID: https://orcid.org/0009-0004-7809-4366

 

Natalia V. Petrova – Resident Physician of the Department of Radiation Diagnostic Methods, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation

ORCID: https://orcid.org/0009-0004-7809-4366

Natullio@yandex.ruhttps://orcid.org/0000-0002-9357-0998КармазановскийГ. Г.KarmazanovskyG. G.

 

Кармазановский Григорий Григорьевич – академик РАН, д.м.н., профессор, заведующий отделением лучевых методов диагностики ФГБУ «Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского», г. Москва, Российская Федерация; профессор кафедры лучевой диагностики и терапии медико-биологического факультета ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России, г. Москва, Российская Федерация

ORCID: https://orcid.org/0000-0002-9357-0998, SPIN: 5964-2369, AuthorID: 338639, Scopus Author ID: 55944296600

 

Grigory G. Karmazanovsky – Academician RAS, Dr. Sci. (Medicine), Professor, Head of the Department of Radiation Diagnostic Methods, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation; Professor of the Department of Radiation Diagnostics and Therapy of the Faculty of Medicine and Biology, Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation, Moscow, Russian Federation

ORCID: https://orcid.org/0000-0002-9357-0998, SPIN: 5964-2369, AuthorID: 338639, Scopus Author ID: 55944296600

https://orcid.org/0000-0001-7070-3391КондратьевЕ. В.KondratyevE. V.

 

Кондратьев Евгений Валерьевич – к.м.н., старший научный сотрудник отделения лучевых методов диагностики ФГБУ «Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского», г. Москва, Российская Федерация

ORCID: https://orcid.org/0000-0001-7070-3391, SPIN: 2702-6526, AuthorID: 243610, Scopus Author ID: 55865664400

 

Evgeny V. Kondratyev – Cand. Sci. (Medicine), Senior Researcher, Department of Radiation Diagnostic Methods, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation

ORCID: https://orcid.org/0000-0001-7070-3391, SPIN: 2702-6526, AuthorID: 243610, Scopus Author ID: 55865664400

https://orcid.org/0000-0001-6267-8237ПоповА. Ю.PopovA. Yu.

 

Попов Анатолий Юрьевич – к.м.н., заведующий отделением противоопухолевой лекарственной терапии ФГБУ «Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского», г. Москва, Российская Федерация

ORCID: https://orcid.org/0000-0001-6267-8237, SPIN: 6197-2060, AuthorID: 1177757, Scopus Author ID: 57192589967

 

Anatoly Yu. Popov – Cand. Sci. (Medicine), Head of the Department of Anticancer Drug Therapy, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation

ORCID: https://orcid.org/0000-0001-6267-8237, SPIN: 6197-2060, AuthorID: 1177757, Scopus Author ID: 57192589967

https://orcid.org/0000-0002-5032-4164РостовцевМ. В.RostovtsevM. V.

 

Ростовцев Михаил Владиславович – д.м.н., старший научный сотрудник отделения лучевых методов диагностики ФГБУ «Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского», г. Москва, Российская Федерация; профессор кафедры рентгенологии и радиологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, г. Москва, Российская Федерация; заведующий рентгенологическим отделением ГБУЗ «Городская клиническая больница им. М. Е. Жадкевича» Департамента здравоохранения города Москвы, г. Москва, Российская Федерация

ORCID: https://orcid.org/0000-0002-5032-4164, SPIN: 3124-6255, AuthorID: 422734, Scopus Author ID: 58136413100

 

Mikhail V. Rostovtsev – Dr. Sci. (Medicine), Senior Researcher, Department of Radiation Diagnostic Methods, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation; Professor of the Department of Radiology and Roentgenology, Russian Medical Academy of Continuing Professional Education, Moscow, Russian Federation; Head of the Radiology Department, M. E. Zhadkevich City Clinical hospital of the Ministry of Health of Russia, Moscow, Russian Federation

ORCID: https://orcid.org/0000-0002-5032-4164, SPIN: 3124-6255, AuthorID: 422734, Scopus Author ID: 58136413100

https://orcid.org/0000-0002-7857-275XГермановичН. Ю.GermanovichN. Yu.

 

Германович Наталья Юрьевна – к.м.н., врач онколог-маммолог хирургического торакального отделения ФГБУ «Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского», г. Москва, Российская Федерация

ORCID: https://orcid.org/0000-0002-7857-275X, AuthorID: 943797

 

Natalia Yu. Germanovich – Cand. Sci. (Medicine), Oncologist-Mammologist of the Surgical Thoracic Department, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation

ORCID: https://orcid.org/0000-0002-7857-275X, AuthorID: 943797

https://orcid.org/0000-0001-6247-9481КалининД. В.KalininD. V.

 

Калинин Дмитрий Валерьевич – к.м.н., врач-патологоанатом патологоанатомического отделения ФГБУ «Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского», г. Москва, Российская Федерация

ORCID: https://orcid.org/0000-0001-6247-9481, SPIN: 5563-5376, AuthorID: 758757, Scopus Author ID: 57224357019, ResearchID: N-9383-2015

 

Dmitry V. Kalinin – Cand. Sci. (Medicine), Pathologist of Anatomical Pathology Department, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation

ORCID: https://orcid.org/0000-0001-6247-9481, SPIN: 5563-5376, AuthorID: 758757, Scopus Author ID: 57224357019, ResearchID: N-9383-2015

Национальный медицинский исследовательский центр хирургии им. А. В. ВишневскогоРоссияA. V. Vishnevsky National Medical Research Center of SurgeryRussian FederationНациональный медицинский исследовательский центр хирургии им. А. В. Вишневского; Российский национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава РоссииРоссияA. V. Vishnevsky National Medical Research Center of Surgery; Pirogov Russian National Research Medical UniversityRussian FederationНациональный медицинский исследовательский центр хирургии им. А. В. Вишневского; Городская клиническая больница им. М. Е. Жадкевича Департамента здравоохранения города Москвы; Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияA. V. Vishnevsky National Medical Research Center of Surgery; M. E. Zhadkevich City Clinical hospital of the Ministry of Health of Russia; Russian Medical Academy of Continuing Professional EducationRussian Federation2023110820231036979Copyright © Петрова Н.В., Кармазановский Г.Г., Кондратьев Е.В., Попов А.Ю., Ростовцев М.В., Германович Н.Ю., Калинин Д.В., 20232023Петрова Н.В., Кармазановский Г.Г., Кондратьев Е.В., Попов А.Ю., Ростовцев М.В., Германович Н.Ю., Калинин Д.В.Petrova N.V., Karmazanovsky G.G., Kondratyev E.V., Popov A.Y., Rostovtsev M.V., Germanovich N.Y., Kalinin D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/901

Рак молочной железы (РМЖ) – наиболее распространенное злокачественное заболевание. Применение неоадъювантной лекарственной терапии повышает вероятность достижения полного патоморфологического ответа (pCR), ведет к повышению резектабельности и абластики; способствует определению чувствительности опухолевых клеток к химиопрепаратам, тем самым улучшая прогноз пациента. Поскольку патоморфологическая оценка происходит после операции, необходимо развитие методов неинвазивной оценки ответа для своевременной коррекции объема проводимого лечения. Одним из таких методов является метод магнитно-резонансной томографии (МРТ). Оценка полученных изображений с использованием текстурного анализа позволяет повысить точность метода как при контроле лечения в неоадъювантном режиме, так и при оценке ответа на назначенную неоадъювантную терапию при предоперационном планировании.

В настоящей статье представлен анализ литературных данных о возможности повышения прогностической ценности МРТ молочных желез в оценке полного патоморфологического ответа при неоадъювантном лекарственном лечении РМЖ с использованием текстурного анализа данных.

Breast cancer (BC) is the most common malignant disease. The use of neoadjuvant drug therapy increases the likelihood of achieving a complete pathomorphological response (pCR), leads to an increase in resectability and ablation; helps to determine the sensitivity of tumor cells to chemopreventive agents, thereby improving the patient’s prognosis. Since pathomorphological assessment occurs aſter surgery, it is necessary to develop methods for non-invasive response assessment for timely correction of the volume of treatment. One such method is magnetic resonance imaging (MRI). Assessment of the obtained images using texture analysis allows to increase the accuracy of the method both in the control of neoadjuvant treatment and in the assessment of the response to neoadjuvant therapy during preoperative planning.

This article provides an analysis of the literature data on the potential to improve the prognostic value of breast MRI in assessing the complete pathomorphological response to neoadjuvant drug treatment of breast cancer using texture analysis of data.

рак молочной железынеоадъювантная терапияМРТпатологический полный ответрадиологический полный ответрадиогеномикатекстурный анализbreast cancerneoadjuvant therapyMRIpathological complete responseradiomicstexture analysisReferencesSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. https://doi.org/10.3322/caac.21660Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. https://doi.org/10.3322/caac.21660Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: Tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 2018 Oct 9;10:4333–4347. https://doi.org/10.2147/cmar.s174435Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: Tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 2018 Oct 9;10:4333–4347. https://doi.org/10.2147/cmar.s174435Puglisi F, Follador A, Minisini AM, Cardellino GG, Russo S, Andreetta C, Di Terlizzi S, Piga A. Baseline staging tests aſter a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol. 2005 Feb;16(2):263–266. https://doi.org/10.1093/annonc/mdi063Puglisi F, Follador A, Minisini AM, Cardellino GG, Russo S, Andreetta C, Di Terlizzi S, Piga A. Baseline staging tests aſter a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol. 2005 Feb;16(2):263–266. https://doi.org/10.1093/annonc/mdi063Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275–1281. https://doi.org/10.1200/jco.2007.14.4147. Epub 2008 Feb 4. Corrected and republished in: J Clin Oncol. 2023 Apr 1;41(10):1809-1815.Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275–1281. https://doi.org/10.1200/jco.2007.14.4147. Epub 2008 Feb 4. Corrected and republished in: J Clin Oncol. 2023 Apr 1;41(10):1809-1815.Funt SA, Chapman PB. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clin Cancer Res. 2016 May 15;22(10):2323–2328. https://doi.org/10.1158/1078-0432.ccr-15-1961Funt SA, Chapman PB. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clin Cancer Res. 2016 May 15;22(10):2323–2328. https://doi.org/10.1158/1078-0432.ccr-15-1961Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27–39. https://doi.org/10.1016/s1470-2045(17)30777-5Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27–39. https://doi.org/10.1016/s1470-2045(17)30777-5Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-172. https://doi.org/10.1016/s0140-6736(13)62422-8. Erratum in: Lancet. 2019 Mar 9;393(10175):986.Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-172. https://doi.org/10.1016/s0140-6736(13)62422-8. Erratum in: Lancet. 2019 Mar 9;393(10175):986.Gradishar WJ, Moran MS, Abraham J, Aſt R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Mar.;23 (Version 4.2023). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfGradishar WJ, Moran MS, Abraham J, Aſt R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Mar.;23 (Version 4.2023). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfKorde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol. 2021 May 1;39(13):1485–1505. https://doi.org/10.1200/jco.20.03399Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol. 2021 May 1;39(13):1485–1505. https://doi.org/10.1200/jco.20.03399Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–2284. https://doi.org/10.1093/annonc/mdt182Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–2284. https://doi.org/10.1093/annonc/mdt182Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13–21. https://doi.org/10.1200/jco.2014.57.0572Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13–21. https://doi.org/10.1200/jco.2014.57.0572Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. Cancers (Basel). 2022 Apr 9;14(8):1898. https://doi.org/10.3390/cancers14081898Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. Cancers (Basel). 2022 Apr 9;14(8):1898. https://doi.org/10.3390/cancers14081898Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-Analysis Confirms Achieving Pathological Complete Response Aſter Neoadjuvant Chemotherapy Predicts Favourable Prognosis for Breast Cancer Patients. Eur J Cancer. 2011;47(14):2084–2090. https://doi.org/10.1016/j.ejca.2011.06.014Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-Analysis Confirms Achieving Pathological Complete Response Aſter Neoadjuvant Chemotherapy Predicts Favourable Prognosis for Breast Cancer Patients. Eur J Cancer. 2011;47(14):2084–2090. https://doi.org/10.1016/j.ejca.2011.06.014Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, et al. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response Aſter Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018;210(6):1376–1385. https://doi.org/10.2214/ajr.17.18323Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, et al. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response Aſter Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018;210(6):1376–1385. https://doi.org/10.2214/ajr.17.18323Gampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, et al. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) aſter neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Breast Cancer Res. 2019 Jan 31;21(1):19. https://doi.org/10.1186/s13058-018-1091-yGampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, et al. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) aſter neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Breast Cancer Res. 2019 Jan 31;21(1):19. https://doi.org/10.1186/s13058-018-1091-yO’Donnell JPM, Gasior SA, Davey MG, O’Malley E, Lowery AJ, McGarry J, et al. The accuracy of breast MRI radiomic methodologies in predicting pathological complete response to neoadjuvant chemotherapy: A systematic review and network meta-analysis. Eur J Radiol. 2022 Dec;157:110561. https://doi.org/10.1016/j.ejrad.2022.110561O’Donnell JPM, Gasior SA, Davey MG, O’Malley E, Lowery AJ, McGarry J, et al. The accuracy of breast MRI radiomic methodologies in predicting pathological complete response to neoadjuvant chemotherapy: A systematic review and network meta-analysis. Eur J Radiol. 2022 Dec;157:110561. https://doi.org/10.1016/j.ejrad.2022.110561Hong J, Rui W, Fei X, Chen X, Shen K. Association of tumor-infiltrating lymphocytes before and aſter neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. Cancer Med. 2021 Nov;10(22):7921–7933. https://doi.org/10.1002/cam4.4302Hong J, Rui W, Fei X, Chen X, Shen K. Association of tumor-infiltrating lymphocytes before and aſter neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. Cancer Med. 2021 Nov;10(22):7921–7933. https://doi.org/10.1002/cam4.4302Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015 Jun 1;75(11):2139–2145. https://doi.org/10.1158/0008-5472.can-15-0255Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015 Jun 1;75(11):2139–2145. https://doi.org/10.1158/0008-5472.can-15-0255Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012 Oct;43(10):1688–1694. https://doi.org/10.1016/j.humpath.2011.12.013Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012 Oct;43(10):1688–1694. https://doi.org/10.1016/j.humpath.2011.12.013Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, Eremin O. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. J Transl Med. 2015 Jun 4;13:180. https://doi.org/10.1186/s12967-015-0535-8Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, Eremin O. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. J Transl Med. 2015 Jun 4;13:180. https://doi.org/10.1186/s12967-015-0535-8Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother. 2012 Feb;61(2):239–247. https://doi.org/10.1007/s00262-011-1148-6Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother. 2012 Feb;61(2):239–247. https://doi.org/10.1007/s00262-011-1148-6Li C, Lu N, He Z, Tan Y, Liu Y, Chen Y, et al. A Noninvasive Tool Based on Magnetic Resonance Imaging Radiomics for the Preoperative Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg Oncol. 2022 Nov;29(12):7685–7693. https://doi.org/10.1245/s10434-022-12034-wLi C, Lu N, He Z, Tan Y, Liu Y, Chen Y, et al. A Noninvasive Tool Based on Magnetic Resonance Imaging Radiomics for the Preoperative Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg Oncol. 2022 Nov;29(12):7685–7693. https://doi.org/10.1245/s10434-022-12034-wGu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis. Clin Breast Cancer. 2017 Jul;17(4):245–255. https://doi.org/10.1016/j.clbc.2016.12.010Gu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis. Clin Breast Cancer. 2017 Jul;17(4):245–255. https://doi.org/10.1016/j.clbc.2016.12.010Cao K, Zhao B, Li XT, Li YL, Sun YS. Texture Analysis of Dynamic Contrast-Enhanced MRI in Evaluating Pathologic Complete Response (pCR) of Mass-Like Breast Cancer aſter Neoadjuvant Therapy. J Oncol. 2019 Dec 26;2019:4731532. https://doi.org/10.1155/2019/4731532Cao K, Zhao B, Li XT, Li YL, Sun YS. Texture Analysis of Dynamic Contrast-Enhanced MRI in Evaluating Pathologic Complete Response (pCR) of Mass-Like Breast Cancer aſter Neoadjuvant Therapy. J Oncol. 2019 Dec 26;2019:4731532. https://doi.org/10.1155/2019/4731532Shukla-Dave A, Obuchowski NA, Chenevert TL, Jambawalikar S, Schwartz LH, Malyarenko D, et al. Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging. 2019 Jun;49(7):e101–e121. https://doi.org/10.1002/jmri.26518Shukla-Dave A, Obuchowski NA, Chenevert TL, Jambawalikar S, Schwartz LH, Malyarenko D, et al. Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging. 2019 Jun;49(7):e101–e121. https://doi.org/10.1002/jmri.26518

The authors declare that there are no conflicts of interest present.